Jump to ContentJump to Main Navigation

Biological Chemistry

Editor-in-Chief: Brüne, Bernhard

Editorial Board Member: Buchner, Johannes / Ludwig, Stephan / Sies, Helmut / Turk, Boris / Wittinghofer, Alfred

12 Issues per year


IMPACT FACTOR increased in 2014: 3.268
Rank 106 out of 289 in category Biochemistry & Molecular Biology in the 2014 Thomson Reuters Journal Citation Report/Science Edition

SCImago Journal Rank (SJR) 2014: 1.596
Source Normalized Impact per Paper (SNIP) 2014: 0.845
Impact per Publication (IPP) 2014: 2.992

VolumeIssuePage

Issues

Pre-clinical development of cell culture (Vero)-derived H5N1 pandemic vaccines

M. Keith Howard1 / Otfried Kistner2 / P. Noel Barrett3

1Baxter AG, Biomedical Research Centre, Uferstrasse 15, A-2304 Orth/Donau, Austria

2Baxter AG, Biomedical Research Centre, Uferstrasse 15, A-2304 Orth/Donau, Austria

3Baxter AG, Biomedical Research Centre, Uferstrasse 15, A-2304 Orth/Donau, Austria

Corresponding author

Citation Information: Biological Chemistry. Volume 389, Issue 5, Pages 569–577, ISSN (Online) 14374315, ISSN (Print) 1431-6730, DOI: 10.1515/BC.2008.060, March 2008

Publication History

Received:
2007-10-17
Accepted:
2008-01-29
Published Online:
2008-03-27

Abstract

The rapid spread of avian influenza (H5N1) and its transmission to humans has raised the possibility of an imminent pandemic and concerns over the ability of standard influenza vaccine production methods to supply sufficient amounts of an effective vaccine. We report here on a robust and flexible strategy which uses wild-type virus grown in a continuous cell culture (Vero) system to produce an inactivated whole virus vaccine. Candidate vaccines based on clade 1 and clade 2 influenza H5N1 strains, produced at a variety of manufacturing scales, were demonstrated to be highly immunogenic in animal models without the need for adjuvant. The vaccines induce cross-neutralising antibodies and are protective in a mouse challenge model not only against the homologous virus but against other H5N1 strains, including those from other clades. These data indicate that cell culture-grown, whole virus vaccines, based on the wild-type virus, allow the rapid high-yield production of a candidate pandemic vaccine.

Keywords: cross-protection; influenza virus; Vero cells; whole virus vaccine

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Nagendra R Hegde
Human Vaccines & Immunotherapeutics, 2015, Volume 11, Number 5, Page 1223
[2]
Catherine J Luke and Kanta Subbarao
Expert Review of Vaccines, 2014, Volume 13, Number 7, Page 873
[3]
Larry R. Smith, Walter Wodal, Brian A. Crowe, Astrid Kerschbaum, Peter Bruehl, Michael G. Schwendinger, Helga Savidis-Dacho, Sean M. Sullivan, Mark Shlapobersky, Jukka Hartikka, Alain Rolland, P. Noel Barrett, and Otfried Kistner
Human Vaccines & Immunotherapeutics, 2013, Volume 9, Number 6, Page 1333
[4]
Ling Tao, JianJun Chen, Jin Meng, Yao Chen, Hongxia Li, Yan Liu, Zhenhua Zheng, and Hanzhong Wang
Virologica Sinica, 2013, Volume 28, Number 3, Page 136
[5]
P Noel Barrett, Daniel Portsmouth, and Hartmut J Ehrlich
Expert Review of Vaccines, 2013, Volume 12, Number 4, Page 395
[6]
Jana Verena Rödig, Erdmann Rapp, Jana Bohne, Michael Kampe, Helene Kaffka, Andreas Bock, Yvonne Genzel, and Udo Reichl
Biotechnology and Bioengineering, 2013, Volume 110, Number 6, Page 1691
[7]
Michael Schotsaert, Xavier Saelens, and Geert Leroux-Roels
Expert Review of Vaccines, 2012, Volume 11, Number 8, Page 949
[8]
Candice Yuen-Yue Chan and Paul Anantharajah Tambyah
Expert Review of Vaccines, 2012, Volume 11, Number 7, Page 759
[10]
Nicolas Sabarth, Helga Savidis-Dacho, Michael G. Schwendinger, Peter Brühl, Daniel Portsmouth, Brian A. Crowe, Otfried Kistner, P. Noel Barrett, Thomas R. Kreil, and M. Keith Howard
Vaccine, 2012, Volume 30, Number 37, Page 5533
[11]
Walter Wodal, Falko G. Falkner, Astrid Kerschbaum, Claudia Gaiswinkler, Richard Fritz, Stefan Kiermayr, Daniel Portsmouth, Helga Savidis-Dacho, Sogue Coulibaly, Christina Piskernik, Christine Hohenadl, M. Keith Howard, Otfried Kistner, P. Noel Barrett, and Thomas R. Kreil
Vaccine, 2012, Volume 30, Number 31, Page 4625
[12]
Fangye Zhou, Jian Zhou, Lei Ma, Shaohui Song, Xinwen Zhang, Weidong Li, Shude Jiang, Yue Wang, and Guoyang Liao
Biochemical and Biophysical Research Communications, 2012, Volume 421, Number 4, Page 850
[13]
Michael L Perdue, Frank Arnold, Sheng Li, Armen Donabedian, Vittoria Cioce, Thomas Warf, and Robert Huebner
Expert Review of Vaccines, 2011, Volume 10, Number 8, Page 1183
[14]
Min-Shi Lee and Alan Yung-Chih Hu
Trends in Microbiology, 2012, Volume 20, Number 3, Page 103
[15]
R. Fritz, N. Sabarth, S. Kiermayr, C. Hohenadl, M. K. Howard, R. Ilk, O. Kistner, H. J. Ehrlich, P. N. Barrett, and T. R. Kreil
Journal of Infectious Diseases, 2012, Volume 205, Number 1, Page 28
[16]
Nicolas Sabarth, M. Keith Howard, Helga Savidis-Dacho, André van Maurik, P. Noel Barrett, and Otfried Kistner
Vaccine, 2010, Volume 28, Number 3, Page 650
[17]
Brian A. Crowe, Peter Brühl, Marijan Gerencer, Michael G. Schwendinger, Andreas Pilz, Otfried Kistner, Katrin Koelling-Schlebusch, Gerald Aichinger, Julia Singer, Markus Zeitlinger, Markus Müller, Hartmut Ehrlich, and P. Noel Barrett
Vaccine, 2010, Volume 29, Number 2, Page 166
[18]
P Noel Barrett, Wolfgang Mundt, Otfried Kistner, and M Keith Howard
Expert Review of Vaccines, 2009, Volume 8, Number 5, Page 607
[19]
Neetu Singh, Aseem Pandey, and Suresh K. Mittal
Expert Reviews in Molecular Medicine, 2010, Volume 12

Comments (0)

Please log in or register to comment.